Literature DB >> 9486614

Individualizing management of aggressive fibromatoses.

M A Spear1, L C Jennings, H J Mankin, I J Spiro, D S Springfield, M C Gebhardt, A E Rosenberg, J T Efird, H D Suit.   

Abstract

PURPOSE: To examine prognostic indicators in aggressive fibromatoses that may be used to optimize case-specific management strategy. METHODS AND MATERIALS: One hundred and seven fibromatoses presenting between 1971 and 1992 were analyzed. The following treatment modalities were utilized: (a) surgery alone for 51 tumors; (b) radiation alone for 15 tumors; and (c) radiation and surgery (combined modality) for 41 tumors. Outcome analysis was based on 5-year actuarial local control rates.
RESULTS: Control rates among surgery, radiation therapy, and combined modality groups were 69%, 93%, and 72%. Multivariate analysis identified age < 18 years, recurrent disease, positive surgical margins, and treatment with surgery alone as predictors for failure. Patients treated with surgery alone had control rates of 50% (3 of 6) for gross residual, 56% for microscopically positive margins, and 77% for negative margins. Radiation and surgery resulted in rates of 59% for gross residual, 78% for microscopically positive margins, and 100% (6 of 6) for negative margins. For recurrent vs. primary tumors, control was achieved in 48% vs. 77%, 90% vs. 100% (5 of 5), and 67% vs. 79% in the Surgery, Radiation, and Combined modality Groups, respectively. Patients presenting with multiple disease sites tended to have aggressive disease. A radiation dose-control relation to > 60 Gy was seen in patients with unresected or gross residual disease. Of the patients, 23 with disease involving the plantar region had a control rate of 62%, with significantly worse outcomes in children.
CONCLUSIONS: These results are consistent with those found in the relevant literature. They support primary resection with negative margins when feasible. Radiation is a highly effective alternative in situations where surgery would result in major functional or cosmetic defects. When negative surgical margins are not achieved in recurrent tumors, radiation is recommended. Perioperative radiation should be considered in other high-risk groups (recurrent disease, positive margins, and plantar tumors in young patients). Doses of 60-65 Gy for gross disease and 50-60 Gy for microscopic residual are recommended. Observation may be considered for primary tumors with disease remaining in situ when they are located such that progression would not cause significant morbidity. Although plantar lesions in children may represent a group at high risk for recurrence or aggressive behavior, the greater potential for radiation-induced morbidity in this group must also temper its use. Given the inconsistent nature and treatment response of this tumor, it is fundamental that treatment recommendations should be made based on the risk:benefit analysis for the individual patient, dependent on tumor characteristics and location, as well as patient characteristics and preferences.

Entities:  

Mesh:

Year:  1998        PMID: 9486614     DOI: 10.1016/s0360-3016(97)00845-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  54 in total

1.  Recurrence patterns and management options in aggressive fibromatosis.

Authors:  Rajaraman Ramamurthy; Balasubramanian Arumugam; Balasubramaniam Ramanandham
Journal:  Indian J Surg Oncol       Date:  2012-05-12

2.  [Aggressive fibromatosis in the jaw and facial region with bone involvement. A review].

Authors:  L Seper; P Hoppe; B Kruse-Lösler; A Büchter; U Joos; J Kleinheinz
Journal:  Mund Kiefer Gesichtschir       Date:  2005-11

3.  Radiotherapy in desmoid tumors : Treatment response, local control, and analysis of local failures.

Authors:  Kirsi Santti; Annette Beule; Laura Tuomikoski; Mikko Rönty; Anna-Stina Jääskeläinen; Kauko Saarilahti; Hanna Ihalainen; Maija Tarkkanen; Carl Blomqvist
Journal:  Strahlenther Onkol       Date:  2017-01-02       Impact factor: 3.621

Review 4.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

5.  [Extra-abdominal desmoid tumors. Case report and literature review].

Authors:  J Ridders; A Ernst; I Todt; R O Seidl
Journal:  HNO       Date:  2005-07       Impact factor: 1.284

6.  Insidious mastalgia hiding a desmoid tumour of the breast.

Authors:  Bella Pajares; Irene Galera; Nuria Ribelles; Matilde Polo
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

7.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

8.  Palliative Resection of a Giant Mesenteric Desmoid Tumor.

Authors:  Jeremy J Sugrue; Stephanie B Cohen; Roland M Marshall; Adam I Riker
Journal:  Ochsner J       Date:  2015

9.  A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.

Authors:  Jae-Cheol Jo; Yong Sang Hong; Kyu-Pyo Kim; Jae-Lyun Lee; Jeeyun Lee; Young Suk Park; Sun Young Kim; Jin-Sook Ryu; Jong-Seok Lee; Tae Won Kim
Journal:  Invest New Drugs       Date:  2014-01-16       Impact factor: 3.850

Review 10.  A systematic review of active treatment options in patients with desmoid tumours.

Authors:  X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier; M Ghert
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.